Literature DB >> 17268643

Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors.

Marcos D García1, A James Wilson, Daniel P G Emmerson, Paul R Jenkins, Sachin Mahale, Bhabatosh Chaudhuri.   

Abstract

The design, synthesis and biological activity of a series of non-planar dihydro-beta-carboline and beta-carboline-based derivatives of the toxic anticancer agent fascaplysin is presented. We show these compounds to be selective inhibitors of CDK4 over CDK2 with an IC50 (CDK4-cyclin D1) = 11 micromol for the best compound in the series 4d. The crystallographic analysis of some of the compounds synthesised (3b/d and 4a-d) was carried out, in an effort to estimate the structural similarities between the designed inhibitors and the model compound fascaplysin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17268643     DOI: 10.1039/b613861f

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  4 in total

1.  4-(3,4-Dihydro-β-carbolin-1-yl)pyrimidin-2-amine.

Authors:  Mat Ropi Mukhtar; Anissuhailin Zainal Abidin; Khalijah Awang; A Hamid A Hadi; Seik Weng Ng
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-02-25

2.  An oxidative amidation and heterocyclization approach for the synthesis of β-carbolines and dihydroeudistomin Y.

Authors:  Suresh Babu Meruva; Akula Raghunadh; Raghavendra Rao Kamaraju; U K Syam Kumar; P K Dubey
Journal:  Beilstein J Org Chem       Date:  2014-02-25       Impact factor: 2.883

3.  Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.

Authors:  Muhammad Imtiaz Shafiq; Thomas Steinbrecher; Ralf Schmid
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

4.  Study of Structure-Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents.

Authors:  Maxim E Zhidkov; Moritz Kaune; Alexey V Kantemirov; Polina A Smirnova; Pavel V Spirin; Maria A Sidorova; Sergey A Stadnik; Elena Y Shyrokova; Dmitry N Kaluzhny; Oleg A Tryapkin; Tobias Busenbender; Jessica Hauschild; Tina Rohlfing; Vladimir S Prassolov; Carsten Bokemeyer; Markus Graefen; Gunhild von Amsberg; Sergey A Dyshlovoy
Journal:  Mar Drugs       Date:  2022-03-02       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.